Watchlist Price Alert

Haemonetics Corporation (HAE)

NYSE: HAE · Real-Time Price · USD

67.98

3.73 (5.81%)

At close: May 08, 2025, 3:59 PM

68.01

0.04%

After-hours: May 08, 2025, 04:07 PM EDT

5.81% (1D)

Bid	65
Market Cap	3.42B
Revenue (ttm)	1.37B
Net Income (ttm)	130.06M
EPS (ttm)	2.54
PE Ratio (ttm)	26.76
Forward PE	12.82
Analyst	Buy

Ask	70
Volume	985,197
Avg. Volume (20D)	834,954
Open	66.82
Previous Close	64.25
Day's Range	65.36 - 69.53
52-Week Range	55.30 - 97.97
Beta	0.32

About HAE

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol HAE

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for HAE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

New

Haemonetics has released their quartely earnings on May 8, 2025:

Revenue of $331M exceeds estimates by $1.62M, with -3.58% YoY decline.

EPS of 1.24 exceeds estimates by 0.02, with 37.78% YoY growth.

Next Earnings Release

Haemonetics Corporation is scheduled to release its earnings on May 8, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 hours ago New

Haemonetics shares are trading higher after the co... Unlock content with Pro Subscription

3 months ago

-11.58%

Haemonetics shares are trading lower after the company reported Q3 financial results and missed its revenue estimate.

News

Just now · zacks.com

Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates

Haemonetics (HAE) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $0.90 per share a year ago.

22 hours ago · zacks.com

Gear Up for Haemonetics (HAE) Q4 Earnings: Wall Street Estimates for Key Metrics

Besides Wall Street's top -and-bottom-line estimates for Haemonetics (HAE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the...

1 week ago · zacks.com

Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?

Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago · zacks.com

4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates

MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release.

1 week ago · businesswire.com

New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced results from a new survey showing that 91% of surveyed adults living with hereditary angioedema (HAE) were...

1 month ago · businesswire.com

KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has licensed com...

1 month ago · businesswire.com

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the completion of enrollment in the open-label KONFIDENT-KID clinical trial of seb...

1 month ago · zacks.com

Is it Apt to Retain HAE Stock in Your Portfolio for Now?

Strong prospects for the Hospital Business and the robust NexSys PCS system bode well for Haemonetics.

2 months ago · seekingalpha.com

Astria Therapeutics: A High-Conviction Bet On HAE

Astria Therapeutics' strong cash position and efficient spending provide a financial runway through mid-2027, reducing dilution risk and supporting pivotal trials for navenibart and STAR-0310. Navenib...